Premix · CP10 · GHRH + GHRP Synergistic Stack · GH Pulse Amplification Protocol
The most widely researched GH secretagogue combination. CJC-1295 amplifies the amplitude of natural GH pulses via the GHRH receptor while Ipamorelin triggers pulse timing via the ghrelin receptor — together producing a GH response significantly greater than either compound alone. Replaces exogenous HGH while preserving the natural GH axis.
CJC-1295 and Ipamorelin work through completely different receptor pathways to achieve the same goal — stimulating the pituitary to release growth hormone. CJC-1295 acts on GHRH receptors (Growth Hormone Releasing Hormone receptors) and amplifies the size of GH pulses. Ipamorelin acts on ghrelin receptors (GHS-R1a) and triggers the timing of GH pulse release. When both pathways are stimulated simultaneously, the resulting GH pulse is significantly larger than either compound produces alone — this is pharmacological synergy, not just additive effects.
The combination is often referred to as CP10 in research contexts and is one of the most extensively documented GH secretagogue protocols available.
CJC-1295 without DAC (also called Modified GRF 1-29) is a synthetic analogue of growth hormone releasing hormone with a short half-life of approximately 30 minutes. This short half-life is a feature, not a bug — it means CJC-1295 produces a sharp, physiological GH pulse that mimics the natural pattern of GH secretion rather than providing a sustained, flat elevation. The version without DAC is specifically preferred over CJC-1295 with DAC because it preserves the natural pulsatile GH release pattern that the body uses for tissue repair, fat metabolism and IGF-1 production.
Published research in healthy adults demonstrated dose-dependent GH increases of 2–10 fold above baseline with corresponding IGF-1 increases of 1.5–3 fold — effects that translate directly to body composition improvement, recovery enhancement and the downstream benefits of optimised GH/IGF-1 signalling.
Ipamorelin is a selective pentapeptide that acts as a ghrelin mimetic — binding GHS-R1a receptors on the pituitary and triggering GH release through a pathway entirely distinct from GHRH. Its key advantage over earlier GHRPs (GHRP-2, GHRP-6) is selectivity — at therapeutic doses Ipamorelin produces robust GH release without meaningfully elevating cortisol, ACTH or prolactin. This clean profile makes it significantly more suitable for extended use than its predecessors.
Exogenous HGH (synthetic growth hormone) provides a flat, sustained supraphysiological elevation of GH that bypasses the pituitary entirely. Over time this suppresses the pituitary's own GH production — the gland atrophies from disuse. When HGH is discontinued the pituitary may take months to recover normal function.
CJC-1295 + Ipamorelin works entirely differently. It stimulates the pituitary to produce and release its own GH in amplified natural pulses. The pituitary remains active and the natural feedback mechanisms remain intact — including the somatostatin negative feedback that prevents GH excess. This means the combination is self-limiting in a way exogenous HGH is not, and the axis remains healthy after discontinuation.
Additionally, the pulsatile GH pattern produced by CJC/Ipam more closely mirrors the natural pattern associated with the anabolic and lipolytic effects of optimised GH — particularly the large nocturnal pulse during slow-wave sleep, which is why bedtime dosing is standard protocol.
The downstream effects of optimised GH/IGF-1 from CJC/Ipam include increased lean body mass through IGF-1 mediated protein synthesis, enhanced lipolysis (fat breakdown) through GH's direct effects on adipose tissue, improved recovery time from training and injury, and improved sleep quality through the amplified slow-wave sleep pulse. In older individuals, the decline in GH production with age is a significant driver of body composition change — CJC/Ipam directly addresses this decline by amplifying the remaining pituitary output rather than replacing it.
IGF-1 directly activates osteoblasts — the cells responsible for building new bone. This is the mechanism by which optimised GH/IGF-1 signalling contributes to bone density maintenance and improvement. Clinical research has documented that GH axis optimisation improves bone mineral density, making CJC/Ipam a relevant addition to protocols targeting osteoporosis and bone health, particularly when combined with compounds that directly target bone matrix (GHK-Cu, BPC-157).
The premix format combines both compounds in a single vial — typically labelled CP10 (5mg CJC + 5mg Ipamorelin per vial). This simplifies the protocol to a single injection rather than two. Batch testing of premix vials (Janoshik analysis) has confirmed accurate compound ratios in quality-sourced premixes. The reconstitution and dosing approach is identical to individual vials — the combined concentration simply means one injection delivers both compounds simultaneously.
Timing is the most critical variable — the compound should be administered at bedtime in a fasted state (2–3 hours after last meal) to maximise the nocturnal GH pulse and avoid the blunting effect of elevated insulin on GH secretion.
As with all GH-axis stimulating compounds, individuals with active cancer or pre-cancerous conditions should exercise caution due to IGF-1's growth-promoting properties. Blood glucose should be monitored in diabetic individuals as elevated GH can temporarily impair insulin sensitivity. The combination increases HSV (herpes) reactivation risk in susceptible individuals through its effects on T-cell immune surveillance — Thymosin Alpha-1 is a targeted co-intervention for this specific concern.